Could These 2 Challenges Derail the AstraZeneca Vaccine? | The Motley Fool
AstraZeneca faces hurdles before entering the U.S. market.
www.fool.com - March 23, 2021
Was AstraZeneca Smart to Sell Its Moderna Shares? | The Motley Fool
It's a definite maybe.
www.fool.com - March 13, 2021
Why AstraZeneca May Dominate the European Vaccine Market | The Motley Fool
Europe is already vaccinating with AstraZeneca's product.
www.fool.com - March 06, 2021
AstraZeneca Just Sold Its Moderna Stock: Should You? | The Motley Fool
Don't be too quick to pull the trigger.
www.fool.com - March 03, 2021
AZN Stock Jumped 3%, WHO Approves AstraZeneca Coronavirus Vaccine for Emergency Use
The WHO has approved two different versions of the AstraZeneca vaccine that were found out to be approximately 63% effective.
www.coinspeaker.com - February 16, 2021
AstraZeneca Wins WHO Emergency Listing For COVID-19 Vaccine; Street Sees 31% Upside
AstraZeneca announced yesterday that the World Health Organization (WHO) has granted an Emergency Use Listing (EUL) for its COVID-19 vaccine. The authorization permits...
www.tipranks.com - February 16, 2021
AZN: Astrazeneca vs. Novavax: Which Vaccine Stock is a Better Buy? | StockNews.com
Astrazeneca PLC(NASDAQ:AZN): Although the FDA has issued Emergency Use Authorizations (EUAs) only for the COVID-19 vaccines developed by Moderna and Pfizer-BioNTech, several other vaccine candidates are still in development. The vaccines developed by Astrazeneca (AZN) and Novavax (NVAX) are still awaiting EUAs, but they reportedly show much promise in their late-stage clinical trials. So, let’s find out which of these two stocks is a better buy now.
stocknews.com - February 12, 2021
AstraZeneca (AZN) Q4 Earnings, Sales Top Despite COVID-19 Woes
AstraZeneca (AZN) surpasses fourth-quarter estimates on both counts. Stock up in pre-market.
www.zacks.com - February 11, 2021
AstraZeneca's COVID Vaccine Is Not a Game-Changer, But the Stock Is Still a 'Buy'
The new coronavirus mutant strains are playing havoc with the already approved Covid-19 vaccines. The latest data shows AstraZeneca’s (AZN) vaccine,
www.smarteranalyst.com - February 10, 2021
AstraZeneca’s COVID Vaccine Is Not a Game-Changer, But the Stock Is Still a ‘Buy’
The new coronavirus mutant strains are playing havoc with the already approved Covid-19 vaccines. The latest data shows AstraZeneca’s (AZN) vaccine, AZD1222 is ineffec...
www.tipranks.com - February 08, 2021
What's in Store for AstraZeneca (AZN) This Earnings Season?
AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales. However, coronavirus-led disruption is likely to have hurt sales.
www.zacks.com - February 08, 2021